HMC-B17

HMC-B17 is a selective, orally bioavailable HPK1 inhibitor (IC50 = 1.39 nM) that potentiates anti-PD-L1 efficacy. HMC-B17 potently enhances the IL-2 secretion in Jurkat cells (EC50 = 11.56 nM) . HMC-B17 can be used for the research of cancer[1].

Product Specifications

CAS Number

[2935913-83-8]

UNSPSC

12352005

Target

MAP4K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hmc-b17.html

Solubility

10 mM in DMSO

Smiles

COC1=C(C=C(C=C1)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)C5CCN(C)CC5)OC

Molecular Formula

C27H29N3O2

Molecular Weight

427.54

References & Citations

[1]Zeng S, et al. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody. Eur J Med Chem. 2024 Mar 5;267:116206.